echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Commun: BCMA/CS1 bispecific CAR can prevent antigen escape during CAR-T treatment of MM

    Nat Commun: BCMA/CS1 bispecific CAR can prevent antigen escape during CAR-T treatment of MM

    • Last Update: 2021-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chimeric antigen receptor (CAR)-T cell therapy has shown significant clinical effects on B-cell malignant tumors, but there are defects in antigen escape and tumor recurrence.


    CAR-T

    Heterogeneous multiple myeloma (MM) that is resistant to B cell maturation antigen (BCMA) traditional CAR-T cell therapy has strong activity, and the results of the study have been published in Nat Commun.


    The results showed that, compared with T cells expressing a single BCMA and CS1 CARs simultaneously, BCMA/CS1 bispecific CAR-T cells showed excellent CAR expression and function.


    In summary, BCMA/CS1 bispecific CAR is a promising treatment method to prevent antigen escape when CAR-T cells treat MM.


     

    Original source:

     

    Eugenia Zah, et al.


    ncbi.
    nlm.
    nih.
    gov/32385241/" target="_blank" rel="noopener">Systematically optimized BCMA / CS1 bispecific CAR- T cells robustly control heterogeneous multiple myeloma

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.